Skip to content

A New Way of Cardiac Denervation to Reduce the Incidence of AF After CABG.

Assessing a New Way of Cardiac Denervation to Reduce the Incidence of Atrial Fibrillation After Coronary Artery Bypass Grafting.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05009914
Enrollment
430
Registered
2021-08-18
Start date
2022-08-15
Completion date
2024-01-30
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Denervation, Postoperative Atrial Fibrillation

Brief summary

This is a prospective, random controlled trial(RCT) study. 430 patients undergoing coronary artery bypass grafting were enrolled. Our new way of cardiac denervation, defined as excision of Marshall ligament and Waterstone fat pad, was performed in 215 patients, and the other 215 patients were used as control subjects. All the patients need to equip with electronic monitor to record heart rhythms within 6 days after CABG. The investigators will compare the incidence of postoperative atrial fibrillation between two groups, and follow up 30 days after discharged.

Interventions

PROCEDUREcardiac denervation

Excision of Marshall ligament and Waterstone fat pad during CABG.

Sponsors

China National Center for Cardiovascular Diseases
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients undergoing simple CABG (on-pump/off-pump) for the first time. 2. Patients who signed the informed consent form and willing to undergo cardiac denervation.

Exclusion criteria

1. Age \< 18; 2. Emergent CABG; 3. Cardiac surgery history; 4. Receiving other cardiac surgery except of CABG at the same time, such as Morrow、valvular surgery、ventricular aneurysm surgery、congenital heart diseases surgery; 5. Requiring mechanical or pharmacological therapy for hemodynamic support before CABG, such as ECMO or IABP; 6. History of AF ; 7. Taking antiarrhythmic agents except of beta-blockers last 2 weeks.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of POAF during hospital.6 days after surgery.Incidence of postoperative atrial fibrillation after surgery during hospital.

Secondary

MeasureTime frameDescription
Incidence of transferring to on-pump CABG caused by cardiac denervation.Intraoperatively.The incidence of transferring to on-pump CABG caused by cardiac denervation during in-hospital time.
Incidence of re-operation aiming to stop bleeding caused by cardiac denervation.Postoperative hospitalization, an average of 8 days.The incidence of re-operation aiming to stop bleeding caused by cardiac denervation during in-hospital time.
Incidence of pericarial effusion within 30 days after discharged.within 30 days after discharged.The incidence of pericarial effusion within 30 days after discharged.
Incidence of massive haemorrhage needing blood transfusion caused by cardiac denervation.Postoperative hospitalization, an average of 8 days.The incidence of massive haemorrhage needing blood transfusion caused by cardiac denervation during in-hospital time.
Postoperative length of hospitalization.Postoperative hospitalization, an average of 8 days.Each participant's oostoperative length of hospitalization.
All cost after surgery.Postoperative hospitalization, an average of 8 days.All cost associated with treatment after surgery during in-hospital time.
MACCEwithin 30 days after discharged.major adverse cardiovascular and cerebrovascular events (MACCE), which was defined as the composite of stroke, myocardial infarction, repeat coronary revascularization and all-cause mortality during the 30-day follow-up.
Incidence of arrhythmia exclude of AF within 30 days after discharged.within 30 days after discharged.The incidence of arrhythmia exclude of AF within 30 days after discharged.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026